{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T22:04:32Z","timestamp":1758924272790,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.urology.2009.09.077","type":"journal-article","created":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T04:21:47Z","timestamp":1286425307000},"page":"927-933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dose-ranging Study of the Luteinizing Hormone-releasing Hormone Receptor Antagonist Cetrorelix Pamoate in the Treatment of Patients With Symptomatic Benign Prostatic Hyperplasia"],"prefix":"10.1016","volume":"76","author":[{"given":"Frans","family":"Debruyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitko","family":"Tzvetkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Altarac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrisor A.","family":"Geavlete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/j.urology.2009.09.077_bib1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/ijir.2008.55","article-title":"Pathology of benign prostatic hyperplasia","volume":"20","author":"Roehrborn","year":"2008","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2009.09.077_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","article-title":"Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7)","volume":"44","author":"Rosen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.urology.2006.04.019","article-title":"Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study","volume":"68","author":"Taylor","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.09.077_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2004.01.015","article-title":"Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients\u2014PERMAL study subset analysis","volume":"45","author":"Debruyne","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0149-2918(07)80077-4","article-title":"A review of combination therapy in patients with benign prostatic hyperplasia","volume":"29","author":"McVary","year":"2007","journal-title":"Clin Ther"},{"issue":"suppl 3","key":"10.1016\/j.urology.2009.09.077_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","article-title":"BPH progression: concept and key learning from MTOPS, ALTESS, combat, and ALF-ONE","volume":"101","author":"Roehrborn","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2009.09.077_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eursup.2006.02.003","article-title":"Inflammation, apoptosis, and BPH: what is the evidence?","volume":"5","author":"Novara","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urology.2009.09.077_bib8","first-page":"183","article-title":"The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia","volume":"8","author":"Lepor","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(17)40591-X","article-title":"Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters","volume":"141","author":"Bosch","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM198709033171004","article-title":"The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia","volume":"317","author":"Peters","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.09.077_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/humupd\/6.4.322","article-title":"The LHRH antagonist cetrorelix: a review","volume":"6","author":"Reissmann","year":"2000","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.urology.2009.09.077_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/pros.2990240206","article-title":"Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer","volume":"24","author":"Gonzalez-Barcena","year":"1994","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2009.09.077_bib13","first-page":"245","article-title":"Clinical and endocrinological results of patients treated with the LHRH antagonist (cetrorelix)","volume":"30","author":"De Reijke","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib14","first-page":"3826","article-title":"Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia","volume":"83","author":"Comaru-Schally","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2009.09.077_bib15","first-page":"531","article-title":"A randomized double blind placebo controlled phase II study of the safety and efficacy of cetrorelix in men with BPH","volume":"157","author":"Lepor","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2008.03.069","article-title":"Placebo-controlled dose-ranging phase II study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia","volume":"54","author":"Debruyne","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C","article-title":"Regulation of prostatic growth and function by peptide growth factors","volume":"28","author":"Culig","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2009.09.077_bib18","first-page":"1031","article-title":"Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice","volume":"5","author":"Shirahige","year":"1994","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urology.2009.09.077_bib19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0022-5347(01)67516-5","article-title":"Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy","volume":"153","author":"Steiner","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.1994.tb02475.x","article-title":"Sustained suppression of serum LH, FSH, and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men","volume":"40","author":"Behre","year":"1994","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.urology.2009.09.077_bib21","first-page":"183","article-title":"The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia","volume":"8","author":"Lepor","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib22","first-page":"505","article-title":"Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia","volume":"74","author":"McConnell","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2009.09.077_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00002512-199710050-00004","article-title":"Benign prostatic hyperplasia","volume":"10","author":"Tammela","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.urology.2009.09.077_bib24","first-page":"3463","article-title":"Hormonal signaling in prostatic hyperplasia and neoplasia","volume":"84","author":"Marcelli","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2009.09.077_bib25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/j.1939-4640.1998.tb02036.x","article-title":"Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH)","volume":"19","author":"Monti","year":"1998","journal-title":"J Androl"},{"key":"10.1016\/j.urology.2009.09.077_bib26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/pros.1072","article-title":"Gonadotropin-releasing hormone receptor expression in the human prostate","volume":"47","author":"Tieva","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2009.09.077_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-5347(08)61318-X","article-title":"Luteinizing hormone-releasing hormone (LHRH) receptors in BPH as potential molecular targets for therapy with cetrorelix","volume":"179","author":"Engel","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.09.077_bib28","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/nm1202-801","article-title":"The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs","volume":"8","author":"Chen","year":"2002","journal-title":"Nat Med"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429509027678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429509027678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:52:29Z","timestamp":1758765149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429509027678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0090429509027678"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2009.09.077","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-ranging Study of the Luteinizing Hormone-releasing Hormone Receptor Antagonist Cetrorelix Pamoate in the Treatment of Patients With Symptomatic Benign Prostatic Hyperplasia","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2009.09.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}